Pain and inflammation is our first commercial focus. Other areas listed here are pipeline or research only. Status labels reflect regulatory and commercial reality, not aspiration.
Across these programs, the common layer is MATRIX Discovery, Electrome's operating internal AI-native R&D software for evidence grounding, hypothesis work, candidate ranking, modeling, controlled experiments, validation, and human scientific review.
Our first commercial focus. FDA-cleared PSWT devices: ActiPatch® (K192234) for musculoskeletal pain including plantar fasciitis heel pain, and RecoveryRx® (K190251) for adjunctive treatment of postoperative pain. Over-the-counter ActiPatch® and clinician-directed RecoveryRx® are both developed and manufactured by BioElectronics Corporation.
Pipeline. Exploring bioelectric signaling for neural inflammation, recovery, and cognitive resilience. No commercial product.
Pipeline. PSWT and related modalities are under evaluation for chronic wound and tissue repair indications, building on existing clinical literature.
Commercial. RecoveryRx® is FDA 510(k) cleared (K190251) for adjunctive treatment of postoperative pain. Available through licensed clinicians as part of Electrome's bioelectric therapy offering.
Commercial and platform program connecting FDA-cleared pulsed shortwave therapy with physical therapy, orthopedic, sports medicine, and home recovery workflows. Delivered through clinician-directed RecoveryRx, FDA 510(k) cleared for adjunctive treatment of postoperative pain.
Pipeline and international development initiative exploring wearable bioelectric therapies for pain, inflammation, pelvic health, and recovery. No FDA-cleared U.S. women's health product.
Research. Exploratory evaluation of bioelectric signaling within inflammation pathways, immune signaling environments, and host response biology, including early stage LymeCure preclinical work. Research only, no clinical or regulated product.
Research. Long horizon exploration of bioelectric signaling within tumor microenvironments and cellular electrophysiology, including a planned melanoma research initiative. Research only, no clinical or regulated product.
Each marker shows the current published status of an area. Research and pipeline areas are not available treatments, and a position here is not a forecast or a timeline.
| Area | Research | Pipeline | Commercial | Status |
|---|---|---|---|---|
| Musculoskeletal Pain | commercial | |||
| Brain Health | pipeline | |||
| Wound Healing | pipeline | |||
| Post Surgical Recovery | commercial | |||
| Recovery & Rehabilitation | commercial | |||
| Women's Health | pipeline | |||
| Infection & Immunology | research | |||
| Oncology Research | research |
Within Infection & Immunology, a research-status area, Lyme research is the first official pathway through MATRIX Discovery.
Lyme research is the first official pathway Electrome reports as having progressed through MATRIX Discovery to peer review. This is a company programme milestone, not independent validation that AI tools caused the result. A platform-selected candidate produced a measurable, replicated in-vitro result on the first day of experiments; peer-reviewed publication followed approximately six months after the initial laboratory work.
This preclinical in-vitro result does not establish a Lyme disease treatment, cure, clinical efficacy, or use in people. No Electrome product is cleared or marketed for Lyme disease or any infectious condition.
Arresting spirochetes: nonthermal extremely low-frequency electromagnetic field exposure suppresses Borrelia burgdorferi motility in vitroElectrome is interested in collaboration across clinical research, technology, distribution, and patient access.
These are the types of clinical, technology, research, and distribution collaboration Electrome is seeking.
Potential collaboration with hospitals, ambulatory surgery centers, orthopedic groups, pain clinics, and rehabilitation networks.
Potential collaboration with retail pharmacies, clinic-in-store teams, DME distributors, and medication fulfillment networks.
Potential collaboration with physical therapy groups, sports medicine practices, post-operative recovery programs, and pain specialists.
Potential collaboration with universities, translational research labs, clinical trial networks, and research institutes.
Interoperability and research-data standards that can support evidence and documentation workflows.
Research hardware, laboratory, and signal-measurement collaboration for controlled scientific studies.
Electrome connects an FDA-cleared commercial foundation in pain with AI-native Discovery R&D. Other application areas shown on this page remain explicitly labeled as research, pipeline, or long-term vision.
